Article
Efficacy and safety of aumolertinib/icotinib combination therapy for naive EGFR-mutant non-small-cell lung cancer patients with brain metastases: A phase I/II study.
Neuro-oncology - 1 Jun 2026
Yu Min, Chen Caini, Gong Youling, Tian Tian, Li Yanying, Fan Hua, Zhang Lizhi, Deng Wen, Liu Yongmei, Peng Feng, Yu Yang, Xiu Weigang, Wang Yongsheng, Zou Bingwen, Zhang Xuanwei, Zhong Liqiang, Liu Tianqiong, Wang Xianfeng, Xu Yong, Zhou Lin, Lu You, Huang Meijuan
Abstract excerpt
BACKGROUND: The benefits of offering first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for treatment-naive EGFR-mutant non-small-cell lung cancer patients (NSCLC) with brain metastases (BMs) are unknown. This trial aims to assess the feasibility, safety, and efficacy of icotinib plus aumolertinib in these patients. METHODS: The phase I/II trial (ChiCTR2100044216)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.